BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is often diagnosed at advanced stage and few patients qualify for resection. Effects of barriers to access on outcomes are unknown. We hypothesized that income and rural residence account for delays in treatment and decreased survival. METHODS: Texas Cancer Registry was queried for ICC patients from 2000 to 2008. Median household income (MHI) and urban/rural status were analyzed. Regression analyses were performed for (1) time-to- treatment (TTT), and (2) overall survival (OS). RESULTS: Among 1,089 patients, 20.2% patients resided in rural areas and MHI ranged $24,497-$81,113/year. Primary treatment included surgery for 9.5%, radiation 5.4% and chemotherapy 21.0%. Median TTT was 29 (range 0-235) days. Patients from low-income areas were less likely to receive treatment (below median MHI, 29.7% vs. above median MHI, 37.5%%; P = 0.007). MHI was associated with TTT (per $10,000/year: hazard ratio (HR) = 1.05; 95% CI: 1.01-1.09). Adjusting for stage, MHI was associated with OS (per $10,000/year: HR = 0.97; 95%CI: 0.94-0.99). Rural residence was neither associated with TTT nor OS. CONCLUSION: Overall treatment rates for ICC patients are low. Regional income, not urbanization was associated treatment and survival independent of stage. Further research is needed to determine how regional prosperity relates to care access.
BACKGROUND:Intrahepatic cholangiocarcinoma (ICC) is often diagnosed at advanced stage and few patients qualify for resection. Effects of barriers to access on outcomes are unknown. We hypothesized that income and rural residence account for delays in treatment and decreased survival. METHODS: Texas Cancer Registry was queried for ICCpatients from 2000 to 2008. Median household income (MHI) and urban/rural status were analyzed. Regression analyses were performed for (1) time-to- treatment (TTT), and (2) overall survival (OS). RESULTS: Among 1,089 patients, 20.2% patients resided in rural areas and MHI ranged $24,497-$81,113/year. Primary treatment included surgery for 9.5%, radiation 5.4% and chemotherapy 21.0%. Median TTT was 29 (range 0-235) days. Patients from low-income areas were less likely to receive treatment (below median MHI, 29.7% vs. above median MHI, 37.5%%; P = 0.007). MHI was associated with TTT (per $10,000/year: hazard ratio (HR) = 1.05; 95% CI: 1.01-1.09). Adjusting for stage, MHI was associated with OS (per $10,000/year: HR = 0.97; 95%CI: 0.94-0.99). Rural residence was neither associated with TTT nor OS. CONCLUSION: Overall treatment rates for ICCpatients are low. Regional income, not urbanization was associated treatment and survival independent of stage. Further research is needed to determine how regional prosperity relates to care access.
Authors: Rachel M Lee; Yuan Liu; Adriana C Gamboa; Mohammad Y Zaidi; David A Kooby; Mihir M Shah; Kenneth Cardona; Maria C Russell; Shishir K Maithel Journal: J Surg Oncol Date: 2019-07-13 Impact factor: 3.454
Authors: Grace C Lee; Cristina R Ferrone; Kenneth K Tanabe; Keith D Lillemoe; Lawrence S Blaszkowsky; Andrew X Zhu; Theodore S Hong; Motaz Qadan Journal: Am J Surg Date: 2019-03-04 Impact factor: 2.565
Authors: Smita Bhatia; Wendy Landier; Electra D Paskett; Katherine B Peters; Janette K Merrill; Jonathan Phillips; Raymond U Osarogiagbon Journal: J Natl Cancer Inst Date: 2022-07-11 Impact factor: 11.816
Authors: Sean C O'Connor; Harveshp Mogal; Gregory Russell; Cecilia Ethun; Ryan C Fields; Linda Jin; Ioannis Hatzaras; Gerardo Vitiello; Kamran Idrees; Chelsea A Isom; Robert Martin; Charles Scoggins; Timothy M Pawlik; Carl Schmidt; George Poultsides; Thuy B Tran; Sharon Weber; Ahmed Salem; Shishir Maithel; Perry Shen Journal: J Gastrointest Surg Date: 2017-10-04 Impact factor: 3.452